Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (1438)	7/25/2002 10:51:33 AM
From: quidditch	Read Replies (1) \| Respond to of 1477

<In NEW YORK story headlined "Scios 2nd-qtr loss widens as costs offset drug sales," please read in last paragraph ...59 cents... instead of ...49 cents ... (Corrects Thomson First Call estimate). A corrected version follows. NEW YORK, July 25 (Reuters) - Scios Inc. (SCIO - news) said on Thursday its second-quarter loss widened as increased research and marketing costs offset higher sales of its heart drug. Scios, based in Sunnyvale, California, said its net loss widened to $22.5 million, or 48 cents a share, from $18.3 million, or 46 cents, a year ago. Revenue rose to $23 million from $5.2 million, lifted by higher sales of Natrecor, the company's treatment for acute heart failure. Analysts had on average expected the company to post a loss of 59 cents a share, according to Thomson First Call. > quid